Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Director | September 03, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2036-09-03 | Direct | 17,000 |
Reported balance
After 2026-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 17,000 · Balance 17,000 F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2: Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,500 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Grant · Acquired 8,500 · Balance 8,500 F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
F2: Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 4, 2026 10:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002075661-26-000002 · form4-09042026_060913.xml · derivative · entry 2 Elze Christian · CIK 0002075661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 10:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0002075661-26-000002 · form4-09042026_060913.xml · derivative · entry 1 Elze Christian · CIK 0002075661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-09-03 F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2 · balance_after: Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-25-023707 · form4-09042025_050915.xml · derivative · entry 2 Elze Christian · CIK 0002075661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-09-03 F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023707 · form4-09042025_050915.xml · nonDerivative · entry 1 Elze Christian · CIK 0002075661 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,500 F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.